SPIMACO's Dammam pharma plant starts trial run

17/04/2017 Argaam

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO) said its Dammam-based pharmaceutical plant has started trial operations for 3-6 months at a total estimated cost of SAR 212 million.

 

The plant has a production capacity of 250 million tablets and 60 million capsules per year, based on one work shift per day, the company said in a statement to the Saudi bourse (Tadawul).

 

The relevant financial impact will be determined later.

 

A total of 23 of SPIMACO’s pharmaceutical products have been registered at the Saudi Food and Drug Authority (SFDA).

 

Last July, the company’s board approved a recommendation from its subsidiary Dammam Pharma to double its capital to SAR 120 million, aimed at completing the Dammam-based pharmaceutical plant.

 

Dammam Pharma is 65 percent-owned by SPIMACO and 20 percent-owned by Arac Healthcare, SPIMACO’s wholly-owned marketing and distribution arm.

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Most Read